RxDoctor Payments Data

Francis Braconaro, MD

Internal Medicine · Lehighton, PANPI 1558349167

Payments from drug & device makers

$834in general payments, 2019–2025

Across 44 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$190
  • GSK$137
  • AbbVie$100
  • Amgen$56
  • Axonics, Inc.$42
  • Exact Sciences$41
  • plus $268 from 11 others

What the payments were for

  • Food & beverage$82799%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$834 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$88,020
Medicare patients
229
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$54,369
JardianceEmpagliflozin33$40,188
EliquisApixaban54$37,844
TrulicityDulaglutide21$27,478
XareltoRivaroxaban41$26,138
MyrbetriqMirabegron25$13,142
OxycontinOxycodone Hcl14$12,833
FarxigaDapagliflozin Propanediol16$12,378
JanuviaSitagliptin Phosphate14$11,679
EntrestoSacubitril/Valsartan15$9,845
Breo ElliptaFluticasone/Vilanterol16$7,879
Incruse ElliptaUmeclidinium Bromide21$7,644
VyvanseLisdexamfetamine Dimesylate12$4,784
MovantikNaloxegol Oxalate11$4,363
Atorvastatin Calcium277$3,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$54,36941 claims
Boehringer IngelheimJardiance$36$40,18833 claims
PfizerEliquis$32$37,84454 claims
Lilly USA, LLCTrulicity$16$27,47821 claims
GSKBreo Ellipta, Incruse Ellipta$137$15,52337 claims
AstraZenecaFarxiga$190$12,37816 claims
AbbVieSynthroid$100$1,22027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lehighton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →